DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways

• Egile Nagusiak: Zaid H. Maayah (Egilea), Ti Zhang (Egilea), Marcus Laird Forrest (Egilea), Samaa Alrushaid (Egilea), Michael R. Doschak (Egilea), Neal M. Davies (Egilea), Ayman O. S. El-Kadi (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2018-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Doxorubicin (DOX) is a very potent and effective anticancer agent. However, the effectiveness of DOX in osteosarcoma is usually limited by the acquired drug resistance. Recently, Vitamin D (Vit-D) was shown to suppress the growth of many human cancer cells. Taken together, we synthesized DOX-Vit D b...